Jefferies analyst Roger Song initiated coverage of Zenas BioPharma with a Buy rating and $35 price target Zenas is a late clinical stage biotech focused on inflammation and immunology-directed opportunities, the analyst tells investors in a research note. The firm says the company’s lead asset is “first-in-class” obexelimab with a differentiated inhibitory mechanism of action for various B-cell driven autoimmune diseases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO: